Market Overview

Mizuho Securities USA Sees Solid Underlying Business Trends For CVS Caremark

Share:

In a report published Monday, Mizuho Securities USA analyst Ann Hynes reiterated a Buy rating and $81.00 price target on CVS Caremark (NYSE: CVS).

In the report, Mizuho Securities USA noted, “We reiterate our Buy rating and $81 price target after a solid 1Q. Upside in the PBM helped offset weakness in retail driven by severe winter weather and a soft flu season. Even including the weather and tough flu comparisons, operating profit trends remain robust with y/y growth and margin expansion. We believe CVS is well positioned to capture share across both operating segments through continued solid execution, and we think earnings visibility is high.”

CVS Caremark closed on Friday at $73.86.

Latest Ratings for CVS

DateFirmActionFromTo
Apr 2019MaintainsStrong BuyStrong Buy
Apr 2019Initiates Coverage OnBuy
Apr 2019DowngradesOutperformPerform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Ann Hynes Mizuho Securities USAAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
APDUpgrades215.0
DPZReiterates325.0
ORLYMaintains435.0
NOWMaintains245.0
MCOMaintains195.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top #PreMarket Losers

UPDATE: MLV & Co Initiates Coverage On pSivida On Multiple Positive Factors